It has been shown that inhibiting TGF-β signaling reduces the number of Tregs and restores the tumour sensitivity to anti-PD-1 and anti-CTLA-4 therapy (132), and blocking TGF-β prior to radiotherapy increases clonogenic cell death and decreases tumour growth (133). The gene discussed is TGFB1; the disease is neoplasm.